Track Cardiol Therapeutics Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Cardiol Therapeutics Inc. CRDL.TO · Stock Open Cardiol Therapeutics Inc. in new tab

2.23 CAD
Add to portfolio
EPS
-0.34
P/B
11.74
ROE
-190.18
Beta
0.61
Target Price
6.00 CAD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateNov. 12, 2026
EPS-0.34
Book Value0.21
Price to Book11.74
Debt/Equity0.45
% Insiders2.363%
Estimates
Forward P/E-7.44
Forward EPS-0.33
Target Mean Price6.00

DCF Valuation

Tweak assumptions to recompute fair value for Cardiol Therapeutics Inc. (CRDL.TO)
Currency: CAD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Cardiol Therapeutics Inc. Logo Cardiol Therapeutics Inc. Analysis (CRDL.TO)

Canada Health Care Official Website Stock

Is Cardiol Therapeutics Inc. a good investment? Cardiol Therapeutics Inc. (CRDL.TO) is currently trading at 2.23 CAD. Market analysts have a consensus price target of 6.00 CAD. This suggests a potential upside from current levels.

Earnings Schedule: Cardiol Therapeutics Inc. is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -0.33.

Investor FAQ

Does Cardiol Therapeutics Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Cardiol Therapeutics Inc.?

Cardiol Therapeutics Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -0.34.

Company Profile

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Exchange Ticker
FRA (Germany) CT9.F
TOR (Canada) CRDL.TO
NMS (United States) CRDL
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion